Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years.
about
Post-transplant dyslipidemia: Mechanisms, diagnosis and managementSalvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer.Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout miceCXCL16 and oxLDL are induced in the onset of diabetic nephropathy.CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoproteinRenal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.Diet-induced increase in plasma oxidized LDL promotes early fibrosis in a renal porcine auto-transplantation model.CD36 in chronic kidney disease: novel insights and therapeutic opportunities.Dietary soy protein benefit in experimental kidney disease is preserved after isoflavone depletion of diet.Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy.Mechanisms and consequences of carbamoylation.
P2860
Q28076119-FFFD6515-7C43-4B75-84A4-F5CA85FB742CQ34442838-21302AE8-5A88-46B9-8FF3-E37077C95B38Q35080598-4F71E664-C37D-4C1C-B3C6-0F5927BA6059Q35893390-8225DBD7-D45A-4109-B3C0-B1B851C420B2Q37197326-C5007ABF-2E50-4F7C-98A4-F0AF1CD5036AQ37216929-0CE6A87C-0A71-420B-97C9-1C8A9D3C7865Q37714689-13A66B44-F6ED-4EFA-98FF-77724B8D892AQ41935783-74CC8C62-FC3C-44BB-BBFA-0ED05C59E293Q42870209-DB3C079A-B68F-4DD7-A059-ED43BFCC7A07Q44311781-5A7915B2-815C-4C56-86F2-26E2EEB933A5Q44530691-6803ED6B-0C0A-4C15-B2DE-A83B5FA7D67DQ48010750-31BF019F-FCCE-469B-B4B5-4610E35266D9
P2860
Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@en
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@nl
type
label
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@en
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@nl
prefLabel
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@en
Oxidative modification of low- ...... nal allografts at 1 1/2 years.
@nl
P2093
P1433
P1476
Oxidative modification of low- ...... enal allografts at 1 1/2 years
@en
P2093
Bosmans JL
Chapelle T
De Broe ME
Van Marck EA
Verpooten GA
P304
P356
10.1046/J.1523-1755.2001.00752.X
P407
P50
P577
2001-06-01T00:00:00Z
P5875
P6179
1046967643